NIOX Group
 | |
| Company type | Public limited company |
|---|---|
| LSE: NIOX | |
| Industry | Medical Devices |
| Founded | 2006[1] |
| Founders | Steve Harris and Charles Swingland[1] |
| Headquarters | Oxford, United Kingdom |
Key people | Ian Johnson (Executive Chairman) Michael Roller (CFO) Jonathan Emms (COO) |
| Products |
|
| Revenue | £36.8 million (2023)[2] |
| Website | www.niox.com |
NIOX Group PLC is a company focussed on treating people suffering from respiratory diseases through its NIOX (Nitric Oxide) range of FeNO (Fractional Exhaled Nitric Oxide) devices which help diagnose and manage asthma.[3] The company is a provider of point-of-care FeNO (Fractional Exhaled Nitric Oxide) measurement and monitoring.[3] It is listed on the London Stock Exchange.
History
[edit]The company was founded by Steve Harris and Charles Swingland as Circassia Group in 2006.[1] It was the subject of an initial public offering in March 2014.[4]
In December 2019, Steve Harris announced that he was resigning as CEO of the company. Ian Johnson took over as Executive Chairman of the company, Michael Roller replaced Julien Cotta as the Chief Financial Officer, and Jonathan Emms, who was appointed to the company in September 2019, became the Chief Operating Officer.[5]
The company also announced its withdrawal from the COPD (chronic obstructive pulmonary disease) business in April 2020, with a proposed transfer of assets to, and termination of agreement with, AstraZeneca for consideration to be set off against debt and accrued interest.[6]
In 2022 the company changed its name from Circassia Group plc to NIOX Group plc.[7]
Operations
[edit]NIOX Group has direct offices in the United Kingdom, United States, Germany, Sweden and China. The company also operates through a distribution model, working with partner companies in order make NIOX available throughout the globe.[8]
NIOX
[edit]NIOX (Nitric Oxide) is a FeNO testing device. Using visual aids and sounds, NIOX provides an easy to use test experience to help patients perform FeNO (Fractional Exhaled Nitric Oxide) tests.[9]
FeNO aids healthcare professionals with the diagnosis and management of asthma.[9]
References
[edit]- ^ a b c "Fundamentals for Circassia Pharmaceuticals Ord 0.08p". The Telegraph. Retrieved 23 August 2014.
- ^ "Final Results 2023". NIOX Group plc. Retrieved 4 December 2024.
- ^ a b "Company". Circassia. Archived from the original on 24 March 2004. Retrieved 29 March 2021.
- ^ "Circassia IPO Fuels Optimism on European Biotech". Wall street Journal. 13 March 2014. Retrieved 23 August 2014.
- ^ "Circassia appoints Jonathan Emms to new COO role". Sharecast. 12 August 2019. Retrieved 29 March 2021.
- ^ "Circassia pulls plug on AZ agreement". PharmaTimes. 9 April 2020. Retrieved 29 March 2021.
- ^ "Circassia Group plc renames to NIOX Group plc". London Stock Exchange. 1 September 2022. Retrieved 23 November 2023.
- ^ "Locations". NIOX. Retrieved 23 November 2023.
- ^ a b "FeNO by NIOX | Enhanced Asthma Management | United States". NIOX.com. Retrieved 29 March 2021.
